[go: up one dir, main page]

WO2007059300A3 - Anti-alk antagonist and agonist antibodies and uses thereof - Google Patents

Anti-alk antagonist and agonist antibodies and uses thereof Download PDF

Info

Publication number
WO2007059300A3
WO2007059300A3 PCT/US2006/044637 US2006044637W WO2007059300A3 WO 2007059300 A3 WO2007059300 A3 WO 2007059300A3 US 2006044637 W US2006044637 W US 2006044637W WO 2007059300 A3 WO2007059300 A3 WO 2007059300A3
Authority
WO
WIPO (PCT)
Prior art keywords
alk
agonist antibodies
agonists
antagonists
disclosure provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/044637
Other languages
French (fr)
Other versions
WO2007059300A2 (en
Inventor
Anton Wellstein
Emma Bowden
Elena Tassi
David Tice
Acqua William Dall
Herren Wu
Changshou Gao
Steven Coats
Jin Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of WO2007059300A2 publication Critical patent/WO2007059300A2/en
Publication of WO2007059300A3 publication Critical patent/WO2007059300A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This disclosure provides ALK antagonists and agonists (e.g., antibodies and antigen-binding portions thereof that bind to ALK), and methods for modulating ALK activity. In other embodiments, the present disclosure provides methods and compositions for using ALK antagonists and agonists to treat various diseases.
PCT/US2006/044637 2005-11-15 2006-11-15 Anti-alk antagonist and agonist antibodies and uses thereof Ceased WO2007059300A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73732405P 2005-11-15 2005-11-15
US60/737,324 2005-11-15

Publications (2)

Publication Number Publication Date
WO2007059300A2 WO2007059300A2 (en) 2007-05-24
WO2007059300A3 true WO2007059300A3 (en) 2007-08-02

Family

ID=37808131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/044637 Ceased WO2007059300A2 (en) 2005-11-15 2006-11-15 Anti-alk antagonist and agonist antibodies and uses thereof

Country Status (1)

Country Link
WO (1) WO2007059300A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
TWI389893B (en) 2007-07-06 2013-03-21 Astellas Pharma Inc Di (arylamino) ary1 compound
WO2010056735A1 (en) * 2008-11-11 2010-05-20 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
CN103237901B (en) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 For treating the biomarker of diagnosis
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
US20160017024A1 (en) * 2013-03-12 2016-01-21 Five Prime Therapeutics, Inc. Fam150a, fam150b, and fam150 antagonists and uses thereof
ES2811927T3 (en) * 2014-04-10 2021-03-15 Memorial Sloan Kettering Cancer Center Novel isoform of anaplastic lymphoma kinase and its uses
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
WO2023278341A1 (en) * 2021-06-28 2023-01-05 Trellis Bioscience, Inc. Anti-alk antibodies & uses thereof
CN115993453B (en) * 2022-07-22 2025-03-25 四川大学 Methods and kits for diagnosis and treatment of RDAA-positive diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096394A2 (en) * 2000-06-14 2001-12-20 Georgetown University Medical Center Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096394A2 (en) * 2000-06-14 2001-12-20 Georgetown University Medical Center Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LEONCINI LORENZO ET AL: "Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity", INTERNATIONAL JOURNAL OF CANCER, vol. 86, no. 6, 15 June 2000 (2000-06-15), pages 777 - 781, XP002424606, ISSN: 0020-7136 *
MOOG-LUTZ CHRISTEL ET AL: "Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 28, July 2005 (2005-07-01), pages 26039 - 26048, XP002424604, ISSN: 0021-9258 *
MOTEGI AKIRA ET AL: "ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth", JOURNAL OF CELL SCIENCE, vol. 117, no. 15, 1 July 2004 (2004-07-01), pages 3319 - 3329, XP002424605, ISSN: 0021-9533 *
STOICA G E ET AL: "Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 20, 18 May 2001 (2001-05-18), pages 16772 - 16779, XP002222815, ISSN: 0021-9258 *
STOICA GERALD E ET AL: "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 39, 27 September 2002 (2002-09-27), pages 35990 - 35998, XP002290577, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2007059300A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2006118772A3 (en) Fcrn antibodies and uses thereof
EA200802168A1 (en) HUMANIZED ANTIBODY TO C-KIT
MX2007002675A (en) Humanized anti-beta7 antagonists and uses therefor.
NO20090047L (en) Anti-DLL4 antibodies and methods for their use
PH12015501848A1 (en) Binding agents
CY1109916T1 (en) Benzimidazolo-thiophene compounds as PLK inhibitors
EA201001223A1 (en) STABILIZED PROTEIN COMPOSITIONS
MY174493A (en) Binding agents
WO2009112245A9 (en) Antibody against the csf-1 r
CU24058B1 (en) PCSK9 ANTAGONISTS
WO2007042573A3 (en) Compositions and methods for treating proliferative disorders
EA201100300A1 (en) COMPOSITIONS AND METHODS INTENDED FOR THE DIRECTED IMPACT OF ANTIBODIES ON C5 COMPLEMENT SYSTEM
WO2007084321A3 (en) Antibodies to ox-2/cd200 and uses thereof
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2007095161A3 (en) Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
WO2007130697A8 (en) Anti-ephb4 antibodies and methods using same
NO20083593L (en) Anti-EphrinB2 antibodies and methods for their use
WO2006096487A3 (en) Methods and compositions for modulating tweak and fn14 activity
WO2007059300A3 (en) Anti-alk antagonist and agonist antibodies and uses thereof
WO2006047269A3 (en) Pharmaceutical compositions
WO2007033374A3 (en) Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
WO2007024744A3 (en) Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
WO2007033140A3 (en) Prok2 antagonists and methods of use
WO2008076916A3 (en) Thallium-sensitive agents and methods of using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837884

Country of ref document: EP

Kind code of ref document: A2